Prediabetes Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
CHAPTER 1. Industry Overview of Prediabetes Market
1.1. Definition and Scope
1.1.1. Definition of Prediabetes
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Prediabetes Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Prediabetes Market By Drug Class
1.2.3. Prediabetes Market By Age group
1.2.4. Prediabetes Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Source
2.2.2. Primary Source
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Prediabetes Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Prediabetes Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Price Trend of Key Raw Material
3.8.1. Raw Material Suppliers
3.8.2. Proportion of Manufacturing Cost Structure
3.8.2.1. Raw Material
3.8.2.2. Labor Cost
3.8.2.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2022
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2022
4.2. R&D Status of Major Manufacturers in 2022
CHAPTER 5. Prediabetes Market By Drug Class
5.1. Introduction
5.2. Prediabetes Revenue By Drug Class
5.2.1. Prediabetes Revenue (USD Million) and Forecast, By Drug Class, 2020-2032
5.2.2. Diguanide
5.2.2.1. Diguanide Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.3. Glucagon-like Peptide-1 Agonists (GLP-1)
5.2.3.1. Glucagon-like Peptide-1 Agonists (GLP-1) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.4. Thiazolidinediones
5.2.4.1. Thiazolidinediones Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.5. DPP-4 Inhibitors
5.2.5.1. DPP-4 Inhibitors Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.6. SGLT2 Inhibitors
5.2.6.1. SGLT2 Inhibitors Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.7. Others
5.2.7.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 6. Prediabetes Market By Age group
6.1. Introduction
6.2. Prediabetes Revenue By Age group
6.2.1. Prediabetes Revenue (USD Million) and Forecast, By Age group, 2020-2032
6.2.2. Children (12-18 years)
6.2.2.1. Children (12-18 years) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.3. Adults (18-49)
6.2.3.1. Adults (18-49) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.4. Elderly (50+)
6.2.4.1. Elderly (50+) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 7. North America Prediabetes Market By Country
7.1. North America Prediabetes Market Overview
7.2. U.S.
7.2.1. U.S. Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
7.2.2. U.S. Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
7.3. Canada
7.3.1. Canada Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
7.3.2. Canada Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
7.4. North America PEST Analysis
CHAPTER 8. Europe Prediabetes Market By Country
8.1. Europe Prediabetes Market Overview
8.2. U.K.
8.2.1. U.K. Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
8.2.2. U.K. Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
8.3. Germany
8.3.1. Germany Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
8.3.2. Germany Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
8.4. France
8.4.1. France Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
8.4.2. France Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
8.5. Spain
8.5.1. Spain Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
8.5.2. Spain Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
8.6. Rest of Europe
8.6.1. Rest of Europe Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
8.6.2. Rest of Europe Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
8.7. Europe PEST Analysis
CHAPTER 9. Asia Pacific Prediabetes Market By Country
9.1. Asia Pacific Prediabetes Market Overview
9.2. China
9.2.1. China Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.2.2. China Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
9.3. Japan
9.3.1. Japan Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.3.2. Japan Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
9.4. India
9.4.1. India Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.4.2. India Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
9.5. Australia
9.5.1. Australia Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.5.2. Australia Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
9.6. South Korea
9.6.1. South Korea Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.6.2. South Korea Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-Pacific Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
9.7.2. Rest of Asia-Pacific Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Prediabetes Market By Country
10.1. Latin America Prediabetes Market Overview
10.2. Brazil
10.2.1. Brazil Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.2.2. Brazil Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
10.3. Mexico
10.3.1. Mexico Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.3.2. Mexico Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
10.4. Rest of Latin America
10.4.1. Rest of Latin America Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
10.4.2. Rest of Latin America Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
10.5. Latin America PEST Analysis
CHAPTER 11. Middle East & Africa Prediabetes Market By Country
11.1. Middle East & Africa Prediabetes Market Overview
11.2. GCC
11.2.1. GCC Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
11.2.2. GCC Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
11.3. South Africa
11.3.1. South Africa Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
11.3.2. South Africa Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & Africa Prediabetes Revenue (USD Million) and Forecast By Drug Class, 2020-2032
11.4.2. Rest of Middle East & Africa Prediabetes Revenue (USD Million) and Forecast By Age group, 2020-2032
11.5. Middle East & Africa PEST Analysis
CHAPTER 12. Player Analysis Of Prediabetes Market
12.1. Prediabetes Market Company Share Analysis
12.2. Competition Matrix
12.2.1. Competitive Benchmarking Of Key Players By Price, Presence, Market Share, And R&D Investment
12.2.2. New Product Launches and Product Enhancements
12.2.3. Mergers And Acquisition In Global Prediabetes Market
12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13. Company Profile
13.1. RESVERLOGIX
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Revenue (USD Million), 2022
13.1.3.2. RESVERLOGIX 2022 Prediabetes Business Regional Distribution
13.1.4. Product/Service and Specification
13.1.5. Recent Developments & Business Strategy
13.2. Valbiotis
13.3. Caelus Health
13.4. Novo Nordisk
13.5. Boston Therapeutics
13.6. SciMar
13.7. Aphaia Pharma
13.8. Bristol-Myers Squibb
13.9. AstraZeneca.
Frequently Asked Questions
How big is the prediabetes market?
The prediabetes market size was USD 191 Million in 2022.
What is the CAGR of the global prediabetes market from 2023 to 2032?
The CAGR of prediabetes is 7.1% during the analysis period of 2023 to 2032.
Which are the key players in the prediabetes market?
The key players operating in the global market are including RESVERLOGIX, Valbiotis, Caelus Health, Novo Nordisk, Boston Therapeutics, SciMar, Aphaia Pharma, Bristol-Myers Squibb, and AstraZeneca.
Which region dominated the global prediabetes market share?
North America held the dominating position in prediabetes industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of prediabetes during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global prediabetes industry?
The current trends and dynamics in the prediabetes market growth include increasing consumer awareness about personal grooming, rising disposable income and urbanization, and advancements in cosmetic technology and formulations.
Which drug class held the maximum share in 2022?
The diguanides drug class held the maximum share of the prediabetes industry.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
